Citations

Clear

3 citation(s) found for "Shin, Kyung-Min".

Efficacy and safety of Tuina for chronic nonspecific low back pain: A PRISMA-compliant systematic review and meta-analysis
Yang, Juan , Zhou, Xuan , Ma, Qingyu , Woods, Jeffrey , Mohabbat, Arya B. , Do, Alexander , Brault, Jeffrey S. , Jensen, Mark A. , Shin, Kyung-Min , Shen, Longbin , Zhao, Canghuan , Cheong, Philip , He, Kejie , Guo, Yu , Chen, Zhuoming , Tang, Yong , Tan, Celia Ia Choo , Bauer, Brent A. , Woods, Jeffrey T., Tang, Shujie , Chen, Jiaxu

Mayo Clinic

Medicine | March 2, 2023 | Volume: 102 | Issue: 9 | Pages: e33018

10.1097/md.0000000000033018 | PMID 36862888 Get It

Objective: Chronic nonspecific low back pain (CNLBP) is a serious medical and social problem resulting in functional decline and decreased work ability. Tuina, a form of manual therapy, has been sparsely used to treat patients with CNLBP. To systematically assess the efficacy and safety of Tuina for patients with CNLBP. Methods: Multiple English and Chinese literature databases were searched until September 2022 for randomized controlled trials (RCTs) of Tuina in the treatment of CNLBP. The methodological quality was assessed using the Cochrane Collaboration’s tool, and certainty of the evidence was determined with the online Grading of Recommendations, Assessment, Development and Evaluation tool. Results: Fifteen RCTs with 1390 patients were included. Tuina demonstrated a significant effect on pain (SMD: −0.82; 95% CI −1.12 to −0.53; P < .001; I 2 = 81%) and physical function (SMD: −0.91; 95% CI −1.55 to −0.27; P = .005; I 2 = 90%) when compared to control. However, Tuina resulted in no significant improvement for quality of life (QoL) (SMD: 0.58; 95% CI −0.04 to 1.21; P = .07; I 2 = 73%;) compared to control. The Grading of Recommendations, Assessment, Development and Evaluation evidence quality was determined to be low level for pain relief, physical function, and QoL measurements. Only six studies reported adverse events; none were serious. Conclusion: Tuina might be an effective and safe strategy for treating CNLBP in terms of pain and physical function, but not for QoL. The study results should be interpreted with caution for their low-level evidence. More multicenter, large-scale RCTs with a rigorous design are required to further confirm our findings.
Dietary Supplements for Pain Relief in Patients with Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Lim, Kia Teng , Lim, Kia Hui , Zhou, Xuan , Yang, Juan , Shin, Kyung-Min , Mohabbat, Arya B. , Baude, Wyatt W., Nanda, S. , Bauer, David A, Theberath, Monique, Theberath, Nicole, Bauer, Brent A. , Ganesh, Ravindra

Mayo Clinic

The American Journal of Chinese Medicine | June 1, 2022 | Volume: 50 | Issue: 05 | Pages: 1197-1218

10.1142/s0192415x22500495 | PMID 35642461 Get It

Pain is the most frequently encountered symptom by patients with fibromyalgia (FM). Dietary supplements (DSs) in particular have a proven impact as a possible adjunctive therapy for symptom management in FM. However, there is currently no conclusive review outlining the evidence for DSs in pain management in FM. This study aims to assess currently available studies evaluating the use of DSs for pain relief in FM. Randomized controlled trials regarding the use of DSs on adult FM patients were included for evidence synthesis. Study results indicated that DSs significantly relieved pain in FM (SMD 1.23; 95% CI 0.02–2.43, P = 0.046) but did not improve quality of life (QoL) (SMD 0.73; 95% CI −0.07–1.53, P = 0.075) in the data. Adverse events of DSs varied from mild to severe, with the most common being gastrointestinal symptoms and androgenic side effects in 5.7% and 3.9% of patients, respectively. More well-designed RCTs are required in the future. The protocol for this review has been published on PROSPERO (CRD42020149941).
Ginseng for the Treatment of Chronic Fatigue Syndrome: A Systematic Review of Clinical Studies
Yang, Juan , Shin, Kyung-Min, Dabrh, Abd Moain Abu , Bierle, Dennis M, Zhou, Xuan, Bauer, Brent A. , Mohabbat, Arya B, Abu Dabrh, Abd Moain , Yang, Juan , Shin, Kyung-Min, Bierle, Dennis M, Zhou, Xuan, Bauer, Brent A , Mohabbat, Arya B

Mayo Clinic

Global Advances in Health and Medicine | February 14, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2164957x221079790 | PMID 35186446 Get It

Background Chronic fatigue syndrome (CFS) is a complex and often disabling chronic condition emerging worldwide, with no curative or definitive therapy yet identified. Ginseng has been widely used to treat fatigue in other patient groups and conditions; however, a systematic review focusing solely on the impact of ginseng on fatigue in patients with CFS has not been performed. Objective This study aimed to assess the current state of evidence regarding ginseng for CFS. Methods Multiple databases were searched from inception to October 2020. All data was extracted independently and in duplicates. Outcomes of interest included the effectiveness and safety of ginseng in patients with CFS. Results 2 studies enrolling 68 patients were deemed eligible, including one randomized clinical trial and one prospective observational study. The certainty of evidence in the effectiveness outcome was low and moderate from both studies, while the safety evidence was very low as reported from one study. Conclusion Study findings highlight a potential benefit of ginseng therapy in the treatment of CFS. However, we are not able to draw firm conclusions due to limited clinical studies. The paucity of data warrants limited confidence. There is a need for future rigorous studies to provide further evidence.